Orion Oyj/€ORNBV

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Orion Oyj

Orion Oyj, established in 1917 and headquartered in Espoo, Finland, is a globally operating pharmaceutical company specializing in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). ([orion.fi](https://www.orion.fi/en/about-orion?utm_source=openai)) The company's product portfolio includes treatments for central nervous system disorders, oncology, respiratory diseases, and urology, with notable products such as Nubeqa for prostate cancer, Stalevo for Parkinson's disease, and the Easyhaler range for asthma and chronic obstructive pulmonary disease. ([stockanalysis.com](https://stockanalysis.com/quote/otc/ORINY/company/?utm_source=openai)) Orion operates production facilities in Finland, France, and Belgium, and maintains research centers in Finland, the UK, and the US. ([marketscreener.com](https://www.marketscreener.com/quote/stock/ORION-OYJ-1412508/news/Orion-Oyj-Sustainability-Report-orion-financial-statement-documents-2024-49296639/?utm_source=openai)) The company's strategic focus is on expanding its global presence through innovation and partnerships, aiming to address healthcare challenges such as cost pressures and an aging population. ([orion.fi](https://www.orion.fi/en/investors/orion-as-an-investment/strategy-and-purpose?utm_source=openai))

Ticker

€ORNBV

Primary listing

XHEL

Industry

Pharmaceuticals

Headquarters

Espo, Finland

Employees

3,943

ISIN

FI0009014377

Orion Oyj Metrics

BasicAdvanced
€8.9B
25.68
€2.47
0.43
€1.63
2.57%

Bulls say / Bears say

Orion Oyj's Q4 2024 net sales grew by 35.3% year-over-year, driven by the blockbuster success of Nubeka, which exceeded €1 billion in sales. (Investing.com)
The company's stock price surged by 6.39% following the earnings announcement, nearing its 52-week high, indicating strong investor confidence. (Investing.com)
Orion Oyj has maintained dividend payments for 18 consecutive years, currently offering a 3.12% yield, appealing to income-focused investors. (Investing.com)
Despite strong sales growth, Orion Oyj's net profit margin decreased by 27.81% in Q4 2024, raising concerns about profitability. (Google Finance)
The company's free cash flow was negative €73.11 million in Q4 2024, a decline of 245.69% year-over-year, indicating potential liquidity issues. (Google Finance)
Orion Oyj's debt-to-equity ratio stands at 0.25, which, while moderate, suggests a reliance on debt that could be risky in a rising interest rate environment. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €ORNBV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs